Kouo, Theodore MD

Ascension is a comprehensive healthcare network providing compassionate care through a wide array of facilities and dedicated providers across the United States. With 94 hospitals and over 23,000 affiliated providers, Ascension is committed to serving communities with personalized medical services and advanced treatments. Notable stories of patient care exemplify the network's dedication to health and wellness, such as successful treatments for complex conditions including high-risk pregnancies and cancer care. Ascension's hospitals, like Ascension Sacred Heart and Ascension Saint Thomas, leverage advanced medical technologies and expert teams to offer critical support in life-threatening situations. Generated from the website

Scott Krummey earned his B.A. in Molecular Biology at Colgate University. He earned M.D. and Ph.D. degrees from Emory University School of Medicine. He completed residency in Clinical Pathology and fellowship in Histocompatibility & Immunogenetics at Emory University. He is an Associate Director of the Immunogenetics Laboratory at Johns Hopkins. Dr. Krummey’s research interests are in understanding cellular mechanisms of alloimmunity, with a focus on how cosignaling receptors and antigen recognition pathways can be exploited to restrain the lymphocytes that cause graft rejection. His laboratory studies mouse and human graft-specific CD8+ T cells, CD4+ T cells, and B cells using including MHC tetramers, transgenic mouse models, and high-dimensional flow cytometry.

Dr. Stephen J. Meltzer is a Professor of Medicine and Oncology at Johns Hopkins University, Division of Gastroenterology. He is the Director of GI Early Detection Biomarkers Laboratory and a member of the Johns Hopkins Kimmel Cancer Center. His research interests are Gastrointestinal cancer and precancer biomarker discover, development and validation; genomics, epigenomics and bioinformatics, early detection of cancer, outcomes research in cancer and precancer, risk stratification prediction in cancer and precancer, Barrett's esophagus, inflammatory bowel disease-associated cancer, liver cancer and gastric cancer. After receiving degree in Medicine at the State University of New York Medical School, Dr. Meltzer interned at Tulane University in New Orleans and University of Texas Medical Branch in Galveston, TX. He completed his fellowship training program in the University of Colorado and the Lenox Hill Hospital. He was an Assistant Professor in UCLA, Center for Health Science in 1987. Prior to joining the faculty at Johns Hopkins in 2006, he was Professor of Medicine and Pharmacology, Founder and Head of Aero digestive Cancer/Biomarker Program in School of Medicine, University of Maryland at Baltimore. He is an Associate Editor of Cancer Research and a member of the editorial board of Esophageal. He has published 152 original scientific papers in high-impact scientific journals. He also has 43 chapters, review articles, editorials, or letters to the editor; 1 book; and 139 abstracts to his name. He has given a plethora of invited lectures around the world, all involving his principal field of esophageal and gastrointestinal cancer research. He has been the recipient of numerous prestigious national and international awards, including the Robert and Sally D. Funderburg Award in Gastric Cancer Biology and membership in the American Society for Clinical Investigation.Special Interests: Gastrointestinal cancer and precancer biomarker discover, development and validation; genomics, epigenomics and bioinformatics, early detection of cancer, outcomes research in cancer and precancer, risk stratification prediction in cancer and precancer. Barrett's esophagus, inflammatory bowel disease-associated cancer, liver cancer, gastric cancer